Effects of combined deferiprone and desferrioxamine iron chelating therapy in β-thalassemia major end-stage heart failure. A case report

21Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

Despite usual iron chelating therapy based on desferrioxamine, patients affected by β-thalassemia major (β-TM) often develop progressive heart failure caused by myocardial iron overload, which is the leading cause of mortality within the third decade of life. Heart transplantation is a limited therapeutic option, as very often these patients have multi-organ iron deposits and infective complications (particularly hepatitis C), secondary to frequent blood transfusions. We report the case of a 26-year-old male affected by β-TM with end-stage heart failure, who showed a dramatic improvement in symptoms and myocardial function when a new oral iron chelating agent, deferiprone, was added to standard therapy with desferrioxamine. © 2006 European Society of Cardiology.

Cite

CITATION STYLE

APA

Porcu, M., Landis, N., Salis, S., Corda, M., Orrù, P., Serra, E., … Galanello, R. (2007). Effects of combined deferiprone and desferrioxamine iron chelating therapy in β-thalassemia major end-stage heart failure. A case report. European Journal of Heart Failure, 9(3), 320–322. https://doi.org/10.1016/j.ejheart.2006.08.006

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free